King's Health Economics, PO24 David Goldberg Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London, SE5 8AF, UK.
Pharmacoeconomics. 2017 Sep;35(9):921-936. doi: 10.1007/s40273-017-0515-3.
Schizophrenia is a chronic and debilitating mental illness characterised by periods of relapse that require resource intensive management. Quantifying the cost of relapse is central to the evaluation of the cost effectiveness of treating schizophrenia.
We aimed to undertake a comprehensive search of the available literature on the cost of relapse.
We performed a search on multiple databases (MEDLINE, Embase, PsycINFO and Health Management Information Consortium) for any study reporting a cost of relapse or data from which such a cost could be calculated. Costs are reported in 2015 international dollars.
We found 16 studies reporting costs associated with relapse over a defined period of time and identified a cost associated with hospitalisation for relapse in 43 studies. Eight clinical decision analyses also provided cost estimates. Studies from the US report excess costs of relapse of $6033-$32,753 (2015 Purchasing Power Parity dollars [PPP$]) over periods of 12-15 months. European studies report excess costs of $8665-$18,676 (2015 PPP$) over periods of 6-12 months. Estimates of the cost of hospitalisation for relapse are more diverse, and associated with marked differences in typical length of stay across jurisdictions.
Wide ranges in the estimated cost of relapse may reflect differences in sample section and relapse definition as well as practice styles and differences in resource costs. Selection of the most appropriate cost estimate should be guided by the definition of relapse and the analysis setting.
精神分裂症是一种慢性且使人虚弱的精神疾病，其特征是反复发作，需要资源密集型管理。量化复发的成本是评估治疗精神分裂症成本效益的核心。
我们旨在全面搜索有关复发成本的现有文献。
我们在多个数据库（MEDLINE、Embase、PsycINFO 和 Health Management Information Consortium）上进行了搜索，以查找报告复发成本或从中可以计算出此类成本的任何研究。成本以 2015 年国际元报告。
我们发现了 16 项研究报告了在特定时间段内与复发相关的成本，并在 43 项研究中确定了与复发住院相关的成本。八项临床决策分析也提供了成本估算。来自美国的研究报告称，在 12-15 个月的时间内，复发的超额成本为 6033-32753 美元（2015 年购买力平价美元 [PPP$]）。欧洲的研究报告称，在 6-12 个月的时间内，复发的超额成本为 8665-18676 美元（2015 年 PPP$）。复发住院成本的估计值更加多样化，并且与司法管辖区内典型住院时间的显著差异相关。
复发成本的估计范围广泛可能反映了样本选择和复发定义以及实践方式和资源成本差异的差异。最合适的成本估算的选择应根据复发的定义和分析设置来指导。
